Mumbai, December 2 (Udaipur Kiran): Wockhardt was trading sharply higher at Rs. 1,504.25 on the BSE, up by 33.35 points or 2.27 per cent from its previous close of Rs. 1,470.90.

The stock opened at Rs. 1,492.95 and moved between a high of Rs. 1,566.95 and a low of Rs. 1,467.80 during the session. So far, 11,02,017 shares have been traded on the counter.

The BSE Group ‘A’ stock, with a face value of Rs. 5, has touched a 52-week high of Rs. 1,870.00 on June 12, 2025, and a 52-week low of Rs. 1,109.60 on February 28, 2025. Over the past one week, the stock has traded between Rs. 1,226.15 and Rs. 1,566.95. The company’s current market capitalisation stands at Rs. 24,429.07 crore.

Promoters hold 49.08 per cent stake in the company, while institutional and non-institutional investors hold 18.12 per cent and 32.80 per cent respectively.

The United States Food and Drug Administration (USFDA) has formally accepted Wockhardt’s New Drug Application (NDA) for its novel, first-in-class antibiotic Zaynich. The NDA was originally filed on September 30, 2025. This marks the first time that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA.

Zaynich has also received Fast Track designation from the USFDA, under which the drug will be given priority during the review process. Based on a novel β-lactam enhancer mechanism, Zaynich has shown strong activity against highly resistant Gram-negative pathogens. Its use has already been demonstrated in critically ill patients in India and the United States under compassionate use.

Wockhardt is a research-based global pharmaceutical and biotechnology company.

Related